Drug Trial Radar · NCT07033481
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 2, 2025
Primary completion
Sep 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- EIP Pharma IncIndustry
- Sponsor type
- Industry
- Collaborators
- CervoMed, Inc.
- First posted
- Jun 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
Conditions
- Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Interventions
NeflamapimodDrug
Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α)
PlaceboDrug
Placebo is a capsule that looks just like neflamapimod but without the active ingredients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events and Serious Adverse Events.Time frame: Baseline to Week 36
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Northwestern Memorial Hospital
Chicago, Illinois
Mayo Clinic
Rochester, Minnesota
Columbia University
New York, New York
The Ohio State University
Columbus, Ohio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Windsor Research Unit, Fulbourn Hospital
Cambridge, United Kingdom
Clinical Ageing Research Unit, Campus for Ageing and Vitality, Biomedical Research Building
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.